AUTH/3715/11/2022 - Complainant v GSK

Allegations about a European Respiratory Society 2022 symposium video

  • Received
    28 November 2022
  • Case number
  • Applicable Code year
  • Completed
    18 December 2023
  • No breach Clause(s)
  • Breach Clause(s)
  • Sanctions applied
    Undertaking received
  • Additional sanctions
  • Appeal
    No appeal

Case Summary

This case concerned a video on a GSK promotional website which summarised the content of GSK’s symposium at the European Respiratory Society Congress 2022 and included data from a GSK network meta-analysis that investigated the comparative efficacy of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) versus other triple and dual therapies for patients with COPD.

Allegations related to misleading comparative claims for GSK’s medicine Trelegy (FF/UMEC/VI) versus other therapies and also that health professionals had been paid to make misleading claims.

The outcome under the 2021 Code was:

Breach of Clause 5.1

Failing to maintain high standards

Breach of Clause 6.1 (x4)

Making a misleading claim

Breach of Clause 6.2 (x2)

Making a claim incapable of substantiation

Breach of Clause 14.1 (x4)

Making a misleading comparison

No Breach of Clause 2

Requirement that activities or materials must not bring discredit upon, or reduce confidence in, the pharmaceutical industry

No Breach of Clause 5.1

Requirement to maintain high standards at all times

No Breach of Clause 6.6 (x2)

Requirement that another company’s medicines must not be disparaged

This summary is not intended to be read in isolation.
For full details, please see the full case report below.